Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques
- PMID: 18374101
- PMCID: PMC2638761
- DOI: 10.1016/j.transproceed.2008.01.039
Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques
Abstract
Suberoylanilide hydroxamic acid (SAHA) a histone deacetylase inhibitor (HDACi), is clinically approved for treatment of cutaneous T-cell lymphoma. Although the exact underlying mechanisms are unknown, HDACi arrests the cell cycle in rapidly proliferating tumor cells and promote their apoptosis. HDACi were also recently shown to enhance the production and suppressive functions of Foxp3+ regulatory T (Treg) cells in rodents, leading us to begin to investigate the actions of HDACi on rhesus monkey T cells for the sake of potential preclinical applications. In this study, we show that SAHA inhibits polyclonal activation and proliferation of rhesus T cells and that the antiproliferative effects are due to inhibition of T-effector (Teff) cells and enhancement of Treg cells. Cryopreserved rhesus macaque splenocytes were CFSE labeled, stimulated with anti-CD3/anti-CD28 and cultured for 5 days in the presence of varying concentrations of SAHA. Samples were then costained to evaluate CD4 and CD8 expression. Concentrations of SAHA (10 and 5 micromol/L) were toxic to splenocytes. Proliferation was inhibited by 57% in CD4 cells and 47% in CD8 cells when unseparated splenocytes were cultured with 3 micromol/L SAHA. Effector cells alone showed decreased inhibition to proliferation when cultured with 3 micromol/L and 1 micromol/L SAHA when compared to Teff plus Treg cells. Our data suggest that SAHA can be used as part of an immunosuppressive protocol to enhance graft survival by limiting Teff cell proliferation as well as increasing Treg cells, thereby promoting tolerance.
Figures

Similar articles
-
SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.Cell Mol Immunol. 2012 Sep;9(5):390-8. doi: 10.1038/cmi.2012.28. Epub 2012 Aug 27. Cell Mol Immunol. 2012. PMID: 22922441 Free PMC article.
-
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.J Immunol. 2004 Sep 15;173(6):4171-8. doi: 10.4049/jimmunol.173.6.4171. J Immunol. 2004. PMID: 15356168
-
Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors.Transpl Int. 2014 Apr;27(4):408-15. doi: 10.1111/tri.12265. Epub 2014 Feb 10. Transpl Int. 2014. PMID: 24410777
-
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.Antimicrob Agents Chemother. 2014 Nov;58(11):6790-806. doi: 10.1128/AAC.03746-14. Epub 2014 Sep 2. Antimicrob Agents Chemother. 2014. PMID: 25182644 Free PMC article.
-
Histone deacetylase inhibitors and transplantation.Curr Opin Immunol. 2007 Oct;19(5):589-95. doi: 10.1016/j.coi.2007.07.015. Epub 2007 Aug 24. Curr Opin Immunol. 2007. PMID: 17719760 Free PMC article. Review.
Cited by
-
Pathways towards an effective immunotherapy for Parkinson's disease.Expert Rev Neurother. 2011 Dec;11(12):1703-15. doi: 10.1586/ern.11.163. Expert Rev Neurother. 2011. PMID: 22091596 Free PMC article. Review.
-
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.Heliyon. 2024 Jan 17;10(2):e24559. doi: 10.1016/j.heliyon.2024.e24559. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38298714 Free PMC article. Review.
-
SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.Cell Mol Immunol. 2012 Sep;9(5):390-8. doi: 10.1038/cmi.2012.28. Epub 2012 Aug 27. Cell Mol Immunol. 2012. PMID: 22922441 Free PMC article.
-
Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.Acta Biomater. 2018 Apr 15;71:261-270. doi: 10.1016/j.actbio.2018.03.002. Epub 2018 Mar 9. Acta Biomater. 2018. PMID: 29526828 Free PMC article.
-
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.J Neurooncol. 2008 Dec;90(3):309-14. doi: 10.1007/s11060-008-9662-x. Epub 2008 Aug 5. J Neurooncol. 2008. PMID: 18679579 Clinical Trial.
References
-
- Richon VM, O’Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res. 2002;8:662. - PubMed
-
- Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287. - PubMed
-
- Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;7:437. - PubMed
-
- Lam AL, Pazin DE, Sullivan BA. Control of gene expression and assembly of chromosomal subdomains by chromatin regulators with antagonistic functions. Chromosoma. 2005;114:242. - PubMed
-
- Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy. 2005;35:89. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials